




A Age at index date




B Female




C BMI (kg/m2)




D Adult onset



E Current smoker




F Never smoked




● All Mepolizumab ● PP ● Pan


G Pack years




H Blood eosinophil count




I Total IgE (kU/L)




J Patients with ≥ 2 exacerbations



K OCS




L Daily OCS Dose (pred eq.)




● All Mepolizumab ● PP ● Pan


M FEV1 pre-BD (PP)




N FEV1 post-BD (PP)



O FeNO (ppb)



P Nasal polyps



● All Mepolizumab ● PP ● Pan